Cavion And Yale Enroll First Patient In Brain Cancer Clinical Trial
Sunday, October 12, 2014
Cavion LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors and neuropathic pain, enrolled the first patient in a Phase 1b clinical trial with Yale University using the company’s T-type calcium channel drug mibefradil. The trial will introduce a new therapeutic approach to patients with recurrent glioblastoma multiforme (GBM).
The trial is an open label, dose-escalation study that will assess the safety and determine the maximum tolerated dose of mibefradil dihydrochloride, a repositioned anti-hypertensive T-type calcium channel blocker, combined with hypofractionated radiation therapy in subjects with recurrent GBM.
“We believe that inhibiting the T-type calcium channel is a new and powerful approach to treating brain cancer and other solid tumors. It is exciting that the Yale Cancer Center and Dr. Ranjit Bindra are exploring this new therapy,” said Cavion CEO and President Andrew Krouse.
“It’s a highly translational study,” said Dr. Bindra. “We are quite excited, and because of the collaborative nature of Yale, the entire team – neurosurgeons, neuro-oncologists, pathologists and radiation oncologists – are energized and eager to get involved.”